WHO Option B+

Is Option B+ the best choice?

I was surprised to read the Editorial on Palestinian minors in Israeli prisons (March 16, p 876), in which there was no room given for any comment from the Israeli side. As a result, it turned out to be completely one-sided and unbalanced. Checking the facts with the Israeli authorities might have clarifi ed that the UNICEF report in question is already being reviewed in Israel, and many change...

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Objective (s):The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. Materials and Methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples...

[Hepatitis B: who should be treated?].

Current therapy for hepatitis B has a limited effect and can rarely eradicate viral infection (normalization of ALT, nullification of HBV DNA, or seroconversion of HBsAg to anti-HBs). Progress in hepatitis B therapy over the last 5 years did not have much influence in this segment. Modifications in therapeutic indications for both acute and chronic hepatitis B presented below are based on stand...

The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.

OBJECTIVE To estimate the incremental cost over 5 years of a policy switch from the Option B to the Option B+ protocol for the prevention of mother-to-child transmission (PMTCT) of the human immunodeficiency virus (HIV). METHODS Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non-breastfeeding women), of...

efficacy of hepatitis b vaccine in those who lost hepatitis b surface antigen during follow-up